The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1648
April 18, 2022
View Complete Issue         Table of Contents 2019 
Efgartigimod alfa (Vyvgart) for Myasthenia Gravis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Efgartigimod alfa (Vyvgart) for Myasthenia Gravis
April 18, 2022 (Issue: 1648)
Efgartigimod alfa-fcab (Vyvgart – Argenx), a first-in-class neonatal Fc receptor (FcRn) antagonist, has been approved by the FDA for IV treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Efgartigimod alfa (Vyvgart) for Myasthenia Gravis
Article code: 1648e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.